052

  1. T

    Additional Benefits Of Early HIV Treatment Revealed By New HPTN 052 Study

    Study results released by the HIV Prevention Trials Network (HPTN) show additional benefits of early antiretroviral therapy (ART) in HIV clinical outcomes. Expanded analysis of HPTN 052 study data, presented at the XIX International AIDS Conference in Washington, D.C., demonstrated that early...
  2. T

    Anacor Pharmaceuticals Announces GSK Has Initiated Two Phase 2 Trials Of GSK '052 In

    Anacor Pharmaceuticals (NASDAQ:ANAC) announced today that GlaxoSmithKline (GSK) has initiated two separate Phase 2b trials of GSK 2251052, or GSK '052 (formerly referred to as AN3365), in complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI). GSK '052 is...
Back
Top